Press Releases

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine

Johnson & Johnson announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for...

Zydus Cadila announces completion of dosing in Phase I clinical trial of ZyCoV-D

Zydus Cadila, an innovation driven global pharmaceutical company focused on discovering and developing NCEs, Novel Biologicals, Biosimilars and Vaccines, announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe and well tolerated in the...

Sun Pharma launches FluGuard (Favipiravir) in India at Rs. 35 per tablet

Sun Pharmaceutical Industries Limited announced that it has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral...

CRYOPORT Partners with MEDIPAL HOLDINGS to Bring Temperature-Controlled Supply Chain Solutions to the Japanese Market

Cryoport, Inc., a global leader in life sciences supply chain solutions, and MEDIPAL HOLDINGS CORPORATION, Japan's leading pharma wholesaler and distributor announced a multi-year strategic business alliance agreement to create an integrated regenerative medicine supply chain solution in Japan. Cryoport...

Partner Therapeutics Wins $35M DoD Contract for Leukine in COVID-19

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD) to fund two clinical studies of inhaled Leukine® (sargramostim, rhu-Granulocyte Macrophage-Colony Stimulating Factor “GM-CSF”) in...

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing, solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion,...

Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis

Novartis, a leader in immuno-dermatology and rheumatology, announced the EC has granted the approval for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The recommended dose for children up...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read